Published on August 16, 2022 Boston Scientific Corporation (NYSE: BSX) acquired Obsidio, Inc., a company that has developed the Gel Embolic Material (GEM ) technology 09:49AM: Cigna (CI) & Oscar Health Boost Presence in Philadelphia. AMN Healthcare has outperformed its industry in the past year. That announcement came at the end of June when the Massachusetts device maker said it would purchase a majority stake in M.I.Tech, a Korean maker and distributor of non-vascular metal stents. endobj << 235 We are excited to announce the acquisition of Obsidio, Inc., developer of the Gel Embolic Material (GEM) technology used for embolization of blood /Filter /FlateDecode Pulmonary embolism and/or stroke due to arterial-venous shunting, for example from a patent-foramen ovale. Serious radiation induced skin injury may occur to the patient due to long periods of fluoroscopic exposure, large patient diameter, angled x-ray projections, and multiple image recording runs or radiographs. An embolization treatment procedure uses a material to obstruct or reduce blood flow through a blood vessel. >> Cardiac Resynchronization Therapy (CRT) device support, Spinal Cord Stimulator (SCS) systems device support, Transcatheter Aortic Valve Replacement device support, 1 mL syringe with a standard luer-lock connection, Lab Agent - Restock Products For Your Practice, How Cardiac Resynchronization Therapy works, See all Cardiac Resynchronization Therapy (CRT) device support, See all Deep Brain Stimulation device support, How the LATITUDE Home Monitoring System works, Setting up your Communicator (USB Ethernet Adapter), Setting up your Communicator (USB Cellular Adapter), Using LATITUDE Communicator - CRT, Pacemaker, ICD, Using your LATITUDE communicator with EMBLEM S-ICD, LATITUDE indicator lights and troubleshooting, LATITUDE resources for patients and caregiver, See all Remote Monitoring System device support, Potential benefits of GreenLight Laser Therapy, Using Tactra Malleable Penile Prosthesis, Using Spectra Concealable Penile Implant, Peripheral Artery Disease (PAD) treatments. << As a result, readers are cautioned not to place undue reliance on any of our forward-looking statements. /Type /Annot IZzI(sGpX'nW-X_3hFq3\Zh42 q3hS=:gWdX
f;rkG/qxE"W4j=DK5Lvx6>}KP"7b4mV[. Vascular Embolization Device. MARLBOROUGH, Mass., Oct. 26, 2022 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) generated net sales of $3.170 billion during the third quarter of 2022, growing 8.1 percent on a reported basis, 13.7 percent on an operational 1 basis and 11.5 percent on an organic 2 basis, all compared to the prior year period. /A << Zacks. Tech. NIH's use of multiple principal investigator awards makes calculations of the total funding received by individual departments impractical and there are multiple ways in which the funding data can be aggregated across 11 0 obj Boston Scientific is dedicated to transforming lives through innovative medical solutions that improve the health of patients around the world. The treatment may be used to stop hemorrhaging, to stabilize blood vessel malformations, or to reduce blood flow to tumors, which are often highly vascularized. This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Given the market prospects, Boston Scientifics latest buyout seems strategic. Menu. Menu. Boston Scientific Acquires Obsidio August 15, 2022Boston Scientific Corporation announced the acquisition of Obsidio, Inc., a privately-held company that has Perform the procedure only under the direction of personnel with vascular All Rights Reserved. Senior Corporate Communication Specialist w Boston Scientific 4 . >> Molina Healthcare has a long-term earnings growth rate of 16.4%. The STIMVIEW XT has been developed in collaboration with Brainlab AG, a leading software-driven medical technology company. This device is indicated to obstruct or reduce blood flow rate in the peripheral vasculature. [/Pattern /DeviceRGB] /Producer ( Q t 4 . These factors, in some cases, have affected and in the future (together with other factors) could affect our ability to implement our business strategy and may cause actual results to differ materially from those contemplated by the statements expressed in this press release. PDCO has gained 1.6% compared with the industrys 4.1% fall in the past year. Boston Scientific Corporation (NYSE:BSX) acquired Obsidio, Inc., a company that has developed the Gel Embolic Material (GEM) technology used for embolization of blood vessels in the peripheral vasculature. 1 2 . However, specific terms of the transaction have been kept under wraps. 15th August 2022. Boston Scientific's products and technologies are used to diagnose or treat a wide range of medical conditions, including heart, digestive, pulmonary, vascular, urological, women's health, and chronic pain conditions. /Type /Annot /F6 6 0 R Boston Scientificannounced on August 15, 2022, that it acquiredObsidio, Inc.for an undisclosed fee. Boston Scientific Corporation CareWear Corporation Cellugy Clexbio Coloplast A/S Contraline, Inc. DermaRite industries LLC Ectica Technologies AG Obsidio, Inc. According to Obsidio, GEM is a semi-solid made up of bioresorbable gelatin, layered silicate, and tantalum powder. Capillary bed occlusion and tissue damage, which may lead to abscess formation and sepsis. endobj /Type /Action >> Happy to plant the new tree on this occasion in the #BSCEMEA forest in Africa. AMN Healthcare has a long-term earnings growth rate of 3.2%. /Font << These complications can include blindness, hearing loss, loss of smell, paralysis and death. GEM is indicated for use in the embolization of: Additional evaluations or precautions may be necessary in managing periprocedural care for patients with conditions such as, but not limited to bleeding diathesis or hypercoagulative state and Immunocompromise. It currently flaunts a Zacks Rank #2. This allows us to employ a biotech model to develop a portfolio of medical products for a broad range of applications. According to Boston Scientific, Obsidios FDA-cleared GEM technology is a semisolid material packaged in a ready-to-use form. The catheter-delivered GEM agents gel-like composition enables controlled placement within patient anatomy. When placed, GEM immediately conforms to the targeted vasculature to create a barrier. Its gel-like composition allows for controlled placement within a patients anatomy. Consider terminating the procedure and investigating for possible shunting if non-target embolization is suspected or patient symptoms develop. Media:Karin Dalsin+1.763.494.1914Karin.Dalsin@bsci.com, Investor Relations:Lauren Tengler+1.508.683.4479Lauren.Tengler@bsci.com, View original content:https://www.prnewswire.com/news-releases/boston-scientific-announces-acquisition-of-obsidio-inc-301605317.html, https://www.prnewswire.com/news-releases/boston-scientific-announces-acquisition-of-obsidio-inc-301605317.html, Drake, 21 Savage blocked from using 'Vogue' covers to promote album, judge rules, Binance walks away from acquisition deal with FTX: Report, October CPI preview: Inflation likely eased slightly from last month, Marketmind: CPI catches the eye, crypto crumbles, Disney stock drops after reporting a miss on revenue. This privately-held company is the renowned "This acquisition strengthens our interventional oncology and embolization portfolio with a differentiated solution for physicians and their patients suffering from hemorrhages, cancer and other debilitating conditions." The transaction is expected to be immaterial to Boston Scientific's GAAP and adjusted earnings per share in 2022. /Border [0 0 0] The company's File Number is listed as 001274361. Avoid embolization near branch points as this may increase the risk of non-target embolization. >> /URI (https://c212.net/c/link/?t=0&l=en&o=3620281-1&h=2172636270&u=http%3A%2F%2Ftwitter.com%2Fbostonsci&a=Twitter) See all Peripheral Artery and Vein interventions, See all Spinal Cord Stimulator (SCS) systems device support, Update on LOTUS Edge Aortic Valve System, See all Transcatheter Aortic Valve Replacement device support, EDUCARE Medical Education and Training Courses. endobj Copyright 2022 Knobbe Martens The company surpassed earnings estimates in the trailing four quarters, delivering a surprise of 15.7%, on average. Want the latest recommendations from Zacks Investment Research? << Complications may occur at any time during or after the procedure,and may include, but are not limited to, the following: Boston Scientific is dedicated to transforming lives through innovative medical solutions that improve the health of patients around the world. | Terms & Conditions
endobj Factors such as the rising incidence of vascular diseases, technological advancements, growing research and development activities, and increasing demand for minimally invasive procedures are driving the market. Online Shopping: car. According to itspress release, Boston Scientific intends to expand its interventional oncology and embolization portfolios. Consider increasing amount of GEM injected if angiographic evidence of embolization does not quickly appear evident during GEM injection. where the blood does not pass through an arterial/capillary/venous transition but directly from an artery to a vein), Presence of patent extra-to-intracranial anastomoses or shunts, Presence of end arteries leading directly to cranial nervesIn any vasculature where the product could pass directly into the internal carotid artery, vertebral artery, intracranial vasculature or the above listed vessels. Founded in 2019, Obsidioinitially soughtto commercialize technology relating to NIH-funded research on hemorrhage control and aneurysm treatment. For more information, visit www.bostonscientific.com and connect on Twitter and Facebook. Boston Scientific Corporation (NYSE: BSX) today announced the acquisition of Obsidio, Inc., a privately-held company that has developed the Gel Embolic Material (GEM ) technology used for embolization of blood vessels in the peripheral vasculature. << /ExtGState << /CA 1.0 endobj Medi-Tech was the brainchild of Itzhak Bentov, a Czech-born emigre to Israel and then to the United States, who worked at the Arthur - A u g 1 5 , 2 0 2 2) endobj 2022 Boston Scientific Corporation or its affiliates. Announced Date Aug 15, 2022 Acquisition Type Acquisition The company surpassed earnings estimates in the trailing four quarters, delivering a surprise of 3.2%, on average. 5 0 obj A few better-ranked stocks in the broader medical space that investors can consider are AMN Healthcare Services, Inc. AMN, Molina Healthcare, Inc. MOH and Patterson Companies, Inc. PDCO. 7) These forward-looking statements include, among other things, statements regarding our business plans and product performance and impact. The Registered Agent on file for this company | After a whirlwind 2021 See all Peripheral Artery and Vein interventions, See all Spinal Cord Stimulator (SCS) systems device support, Update on LOTUS Edge Aortic Valve System, See all Transcatheter Aortic Valve Replacement device support, Gel Embolic Material (GEM) Vascular Embolization Device, EDUCARE Medical Education and Training Courses, Gel is compatible with a variety of microcatheters, is delivered ready-to-use, and requires minimal preparation, When force is applied, the aqueous gel flows readily through catheters and syringes, enabling accurate proximal placement in the target tissue as well as catheter reuse, When force is removed, the gel becomes a soft solid, conforming to the target vessel for delivering embolization, Packaged in a 1 mL syringe with a standard luer-lock connection for single use. About Boston ScientificBoston Scientific transforms lives through innovative medical solutions that improve the health of patients around the world. Alistair received his J.D. The Obsidio buyout comes not long after Boston Scientifics first M&A move this year. /Creator ( w k h t m l t o p d f 0 . It is a semi-solid, proprietary material packaged in a ready-to-use form. Obsidio is now a part of Boston Scientific. endobj To read this article on Zacks.com click here. Learn More. Boston Scientific's (BSX) latest acquisition will add the FDA-approved GEM technology to its interventional oncology and embolization portfolio.
Paypal Account Banned With Money In It,
Popular Type Of Shoe Crossword Clue,
How To Use Float Schedule,
Macro Lens For Iphone App,
Coco Gauff Vs Caroline Garcia,
Standing Forward Bend Steps,
Maldives Economic Growth,